Sahu Avilash, Zameer M M, Vinay C, Rao Sanjay, D'Cruz Ashley
Department of Pediatric Surgery, Narayana Health, Bengaluru, Karnataka, India.
J Indian Assoc Pediatr Surg. 2024 Jul-Aug;29(4):329-333. doi: 10.4103/jiaps.jiaps_248_23. Epub 2024 Jul 6.
Tunnelled catheters improve venous access in haematological diseases and malignancies, but are associated with complications. We prospectively analysed the episodes of CABSI and its associated risk factors.
To study the incidence and risk factors for CABSI in children with tunnelled central venous catheters (both Hickmans and Chemoports).
This is a prospective observational study done at our institute. Children under the age of 18 who underwent insertion of a Hickman or Chemoport from March 2018 to Dec 2022 were enrolled. Episodes of CABSI were noted and its risk factors were analysed.
In total, 258 catheters were inserted in 250 children. Age ranged from 1 month to 18 years (median 67 months) with 60% being boys. A total of 152 Hickmans, 106 chemoports were inserted. Indications for insertions were for requirement of BMT and chemotherapy in majority of cases. CABSI were seen in 28.6% of catheters. Younger children (< 4years), Neutropenia (counts < 1000) and use of TPN were significantly associated with CABSI(p value<0.05). Infection was more with externalized catheters (Hickman) than implantable ports (Chemoports) but was not statistical significant(p value>0.05). Almost 30% of catheters with CABSI required removal because of florid sepsis. Others could be salvaged with aggressive antibiotics.
CABSI is a serious complications related to tunnelled catheter. Smaller children (<4 years), neutropenia and usage of TPN is a risk factor for development of CABSI. It can be treated with appropriate antibiotics and required removal in almost a third of all the cases.
隧道式导管改善了血液系统疾病和恶性肿瘤患者的静脉通路,但会引发并发症。我们对中心静脉导管相关血流感染(CABSI)事件及其相关危险因素进行了前瞻性分析。
研究带隧道式中心静脉导管(希克曼导管和化疗端口)的儿童发生CABSI的发生率及危险因素。
这是在我们研究所进行的一项前瞻性观察性研究。纳入了2018年3月至2022年12月期间接受希克曼导管或化疗端口置入的18岁以下儿童。记录CABSI事件并分析其危险因素。
共250名儿童置入了258根导管。年龄范围为1个月至18岁(中位年龄67个月),60%为男孩。共置入152根希克曼导管、106个化疗端口。大多数情况下,置入导管的指征是需要进行骨髓移植和化疗。28.6%的导管发生了CABSI。年龄较小的儿童(<4岁)、中性粒细胞减少(计数<1000)和使用全胃肠外营养(TPN)与CABSI显著相关(p值<0.05)。外置导管(希克曼导管)的感染率高于植入式端口(化疗端口),但无统计学意义(p值>0.05)。近30%发生CABSI的导管因严重败血症需要拔除。其他导管可通过积极使用抗生素挽救。
CABSI是与隧道式导管相关的严重并发症。年龄较小的儿童(<4岁)、中性粒细胞减少和使用TPN是发生CABSI的危险因素。可通过适当的抗生素治疗,几乎三分之一的病例需要拔除导管。